Unsurprisingly, Profarma Distribuidora de Produtos Farmacêuticos S.A.'s (BVMF:PFRM3) stock price was strong on the back of its healthy earnings report. However, we think that shareholders may be missing some concerning details in the numbers.
The Impact Of Unusual Items On Profit
For anyone who wants to understand Profarma Distribuidora de Produtos Farmacêuticos' profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from R$91m worth of unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Profarma Distribuidora de Produtos Farmacêuticos.
Our Take On Profarma Distribuidora de Produtos Farmacêuticos' Profit Performance
We'd posit that Profarma Distribuidora de Produtos Farmacêuticos' statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Profarma Distribuidora de Produtos Farmacêuticos' statutory profits are better than its underlying earnings power. But on the bright side, its earnings per share have grown at an extremely impressive rate over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So while earnings quality is important, it's equally important to consider the risks facing Profarma Distribuidora de Produtos Farmacêuticos at this point in time. For instance, we've identified 4 warning signs for Profarma Distribuidora de Produtos Farmacêuticos (1 shouldn't be ignored) you should be familiar with.
Today we've zoomed in on a single data point to better understand the nature of Profarma Distribuidora de Produtos Farmacêuticos' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.